miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair-Deficient Colorectal Cancer by Targeting PD-L1.
Journal
Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
07
08
2018
revised:
16
12
2018
accepted:
11
03
2019
pubmed:
16
3
2019
medline:
2
5
2020
entrez:
16
3
2019
Statut:
ppublish
Résumé
Immunotherapy against the interaction between programmed cell death 1/programmed cell death ligand 1 (PD-L1) has emerged as a promising strategy for colorectal cancer with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). The study aimed to identify miRNAs that posttranscriptionally control PD-L1 expression on tumor cells and also regulate immune evasion. A comprehensive miRNA screening using The Cancer Genome Atlas (TCGA) dataset (
Identifiants
pubmed: 30872332
pii: 1541-7786.MCR-18-0831
doi: 10.1158/1541-7786.MCR-18-0831
doi:
Substances chimiques
3' Untranslated Regions
0
B7-H1 Antigen
0
CD274 protein, human
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1403-1413Informations de copyright
©2019 American Association for Cancer Research.